Humana's 15min Chart Triggers MACD Death Cross, KDJ Death Cross: Stocks Fall

On September 17, 2025 at 12:30, Humana's 15-minute chart exhibited a MACD Death Cross and a KDJ Death Cross, indicating a potential downtrend in the stock price. This suggests that the momentum of the stock price is shifting towards the downside, potentially leading to a further decrease in value.

On September 17, 2025, Humana Inc.'s (NYSE: HUM) 15-minute chart exhibited a MACD Death Cross and a KDJ Death Cross, signaling a potential downtrend in the stock price. These technical indicators suggest that the momentum of Humana's stock price is shifting towards the downside, potentially leading to a further decrease in value.

The MACD (Moving Average Convergence Divergence) Death Cross occurs when the MACD line crosses below the signal line, indicating a potential reversal in the stock's trend. The KDJ (Kaufman Adaptive Moving Average) Death Cross, on the other hand, is a similar indicator that uses the KDJ line to signal a potential change in the stock's momentum. Both indicators have historically been reliable in predicting short-term price movements.

Humana Inc. reported earnings of $6.27 EPS for the last quarter, missing expectations but showing a 9.6% year-over-year increase in revenue to $32.39 billion. Despite the earnings miss, the company declared a quarterly dividend of $0.885 per share, with a dividend yield of 1.3%, to be paid on October 31st. The company's dividend payout ratio (DPR) is 27.17%.

Institutional investors have shown interest in Humana, with several large investors buying and selling shares in the first quarter. Acadian Asset Management LLC bought 14,084 shares valued at approximately $3.73 million, while Cary Street Partners Investment Advisory LLC raised its position by 63.9% to own 118 shares valued at $31,000. Other investors, including Riverview Trust Co, Garde Capital Inc., Zions Bancorporation National Association UT, and Whipplewood Advisors LLC, also acquired new positions in Humana during the first quarter.

Market sentiment towards Humana is mixed, with seven analysts rating the stock as a Buy and sixteen as a Hold. The consensus rating is Hold, with a consensus price target of $289.24. Analysts' opinions vary, with Piper Sandler setting a neutral rating at $272.00, while Sanford C. Bernstein increased their target price to $341.00 with an outperform rating.

Humana's stock opened at $276.36 on Monday, with a market capitalization of $33.24 billion. The company's debt-to-equity ratio is 0.69, and its current and quick ratios are both 1.95. The stock has a one-year low of $206.87 and a one-year high of $325.75. The 50-day simple moving average is $265.34, and the 200-day simple moving average is $257.17.

Given the recent technical indicators and mixed analyst sentiment, investors should closely monitor Humana Inc.'s stock price and earnings reports. The potential downtrend suggested by the MACD and KDJ Death Crosses may indicate a challenging period ahead for the stock, but the company's strong financial performance and institutional support could provide a buffer against further declines.